New vaccine strategy aims to shield spleenless adults from deadly infections
NCT ID NCT02052154
First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tested a two-step pneumococcal vaccine approach in 70 adults who had their spleen removed. Participants received one dose of a conjugate vaccine followed by a second dose of a polysaccharide vaccine two months later. The goal was to see if this combination improved immune response against 9 common pneumococcal bacteria types that can cause serious infections. Results were measured by antibody levels one month after the second shot.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENECTOMIZED PATIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.